Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Active Lifestyles And New Surgical Techniques Driving Sports Medicine Market

Executive Summary

Although the US sports medicine market is dominated by conservative care treatments, new surgical techniques, arthroscopy products and surgical implants are fueling growth in the market, which is projected to reach almost $15.5 billion by 2018. Industry consolidation and dealmaking among orthopedic manufacturers has yielded several partnerships and M&As that have included a sports medicine element.

You may also be interested in...



Market Intel: EU Ortho Close-Up: Rising, But Varying Orthopedic/Spinal Opportunities In 5 European Markets

A rising and more active aging population, and a growing incidence of osteoporosis fractures and back pain – as well as other spine-related issues – are paving the way for companies to bring innovative devices into the hands of orthopedic and spinal surgeons in Spain, Italy, Germany, the UK and France. In this feature, we take a closer look at the prevailing surgical approaches and techniques for selected fracture fixation, spinal surgery procedures, joint replacement, and arthroscopy procedures in each of the five major EU countries, as outlined in a new Meddevicetracker report. We also take a deep dive into the various growth opportunities of select procedures in each EU market and discuss trends.

Innovation Is Alive And Well In Sports Medicine

The sports medicine market comprises a number of product segments, many of which span several different orthopedics specialties.This space is expected to experience strong growth going forward as companies develop innovative ways, including some lower-cost approaches, to treat the joint and soft-tissue injuries commonly suffered by athletes and other sports enthusiasts.

SK Bioscience First To Line In Korea COVID Vaccine Race

SK Bioscience has received the world’s first approval of its in-house developed recombinant protein COVID-19 vaccine SKYCovione (GBP510), in its home market of South Korea, two years after it began development. Strong support from the domestic government and international cooperation helped pave the way.

Topics

Related Companies

Related Deals

Latest News
UsernamePublicRestriction

Register

MT035838

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel